Paltusotine hydrochloride is a Small Molecule owned by Crinetics Pharmaceuticals, and is involved in 12 clinical trials, of which 6 were completed, 4 are ongoing, and 2 are planned.

Paltusotine hydrochloride (CRN-00808) is a somatostatin receptor agonist. Somatostatin has diverse physiological actions, including its role as a central nervous system neurotransmitter and neuromodulator, regulatory hormone in the gastrointestinal tract and pancreas and inhibitor of GH and TSH release in the pituitary. Activity at human SSTR 2 and 5 is the primary mechanism responsible for GH inhibition.

The revenue for Paltusotine hydrochloride is expected to reach a total of $4.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Paltusotine hydrochloride NPV Report.

Paltusotine hydrochloride is originated and owned by Crinetics Pharmaceuticals.

Paltusotine hydrochloride Overview

Paltusotine hydrochloride (CRN-00808) is under development for the treatment of acromegaly and neuroendocrine tumors, carcinoid syndfrome. The drug candidate is administered through oral route. The drug candidate is a  biased nonpeptide acts by targeting somatostatin receptor. The drug candidate was under development for age-related macular degeneration (AMD) and diabetic retinopathy.

Crinetics Pharmaceuticals Overview

Crinetics Pharmaceuticals (Crinetics) is a pharmaceutical company. It developes of novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related cancers. The company’s products portfolio comprises paltusotine (Oral SST2 agonist); CRN04777 (SST5 agonist); and CRN04894 (ACTH agonist). It provides somatostatin agonists for the treatment of pancreatic neuroendocrine tumors, carcinoid tumors, GH secreting adenomas, diabetic retinopathy, graves ophthalmopathy, chronic pain, epilepsy, and dementia. The company provides endocrine drug discovery and development through collaboration with healthcare and research institutes. Crinetics is headquartered in San Diego, California, the US.

The company reported revenues of (US Dollars) US$1.1 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$0.1 million in FY2020. The operating loss of the company was US$107.7 million in FY2021, compared to an operating loss of US$75 million in FY2020. The net loss of the company was US$107.6 million in FY2021, compared to a net loss of US$73.8 million in FY2020. The company reported revenues of US$0.4 million for the second quarter ended June 2022, a decrease of 86% over the previous quarter.

Quick View – Paltusotine hydrochloride

Report Segments
  • Innovator
Drug Name
  • Paltusotine hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Hormonal Disorders
  • Metabolic Disorders
  • Oncology
  • Ophthalmology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.